Recent trials with a “high impact” on current daily practice a 360° journal search
Journal of Current Cardiology · 2024
DOI: 10.4103/jcc.jcc_17_24 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Current Cardiology, 2024. Verfasst von Suman Bhandari und 3 weiteren Autor:innen.
Abstract (Originalsprache)
1) Effect of a Salt Substitute on the Incidence of Hypertension and Hypotension among Normotensive Adults Zhang X, Yuan Y, Li C, Feng X, Wang H, Qiao Q, et al. Effect of a salt substitute on incidence of hypertension and hypotension among normotensive adults. J Am Coll Cardiol 2024;83:711-22. New Question: This study sought to assess the effects of a salt substitute (62.5% NaCl, 25% KCl, and 12.5% flavorings) on the incidence of hypertension and hypotension among older adults with normal blood pressure. Key Findings: Compared with the usual salt group (n = 298), the salt substitute group (n = 313) had a lower hypertension incidence but did not increase the incidence of hypotension episodes. Mean systolic/diastolic blood pressure did not increase from the baseline to the end of intervention in the salt substitute group, resulting in a net reduction of −8.0 mmHg in diastolic blood pressure between intervention groups. Clinical Implication and Meaning: In Chinese older adults with normal blood pressure, replacing usual salt with a salt substitute may reduce the incidence of hypertension without increasing hypotension episodes. This suggests a desirable strategy for population-wide prevention and control of hypertension and cardiovascular disease, deserving further consideration in future studies. 2) Semaglutide in Patients with Obesity-related Heart Failure and Type 2 Diabetes New Question: Obesity and Type 2 diabetes are prevalent in patients with heart failure with preserved ejection fraction and are characterized by a high symptom burden. Are there any approved therapies specifically target obesity-related heart failure with preserved ejection fraction in persons with Type 2 diabetes? Key Findings: A total of 616 participants underwent randomization. The mean change in the Kansas City Cardiomyopathy Questionnaire clinical summary score (KCCQ-CSS) was 13.7 points with semaglutide and 6.4 points with placebo, and the mean percentage change in body weight was − 9.8% with semaglutide and − 3.4% with placebo. The results for the confirmatory secondary end points favoured semaglutide over placebo (estimated between-group difference in change in 6-minute walk distance, 14.3 m win ratio for hierarchical composite end point, 1.58; and estimated treatment ratio for change in CRP level, 0.67 . Serious adverse events were reported in 55 (17.7%) participants in the semaglutide group and 88 (28.8%) in the placebo group. Clinical Implication and Meaning: Among patients with obesity-related heart failure with preserved ejection fraction and Type 2 diabetes, semaglutide led to larger reductions in heart failure-related symptoms and physical limitations and greater weight loss than placebo at 1 year. 3) Safety and Tolerability of Inclisiran for Treatment of Hypercholesterolemia in 7 Clinical Trials New Question: The purpose of this study was to provide reliable evidence to date on the long-term safety profile of inclisiran. Key Findings: This analysis included 3576 patients treated with inclisiran for up to 6 years and 1968 patients treated with placebo for up to 1.5 years, with 9982.1 and 2647.7 patient-years of exposure, respectively. Baseline characteristics were balanced between groups. The Kaplan–Meier analyses showed that treatment-emergent adverse events (TEAEs) were serious or led to discontinuation; hepatic, muscle, and kidney events; incident diabetes; and elevations of creatine kinase or creatinine accrued at a comparable rate between groups for up to 1.5 years, with similar trends continuing for inclisiran beyond this period. Numerically, fewer major cardiovascular events reported as TEAEs occurred with inclisiran during this period. Treatment-induced antidrug antibodies were uncommon with inclisiran (4.6%), with few of these persistent (1.4%) and not associated with a greater incidence of TEAEs leading to study drug discontinuation or serious TEAEs. Clinical Implication and Meaning: Long-term treatment with inclisiran was well tolerated in a diverse population, without new safety signals, supporting the safety of inclisiran in patients with dyslipidemia. 4) Phase 2 Study of Aficamten in Patients with Obstructive Hypertrophic Cardiomyopathy Maron MS, Masri A, Choudhury L, Olivotto I, Saberi S, Wang A, et al. Phase 2 study of aficamten in patients with obstructive hypertrophic cardiomyopathy. J Am Coll Cardiol 2023;81:34-45. New Question: This study aims to evaluate the safety and efficacy of aficamten in patients with obstructive hypertrophic cardiomyopathy (oHCM). Key Findings: From baseline to 10 weeks, aficamten reduced gradients at rest and with Valsalva. There were modest reductions in ejection fraction .Symptomatic improvement in ≥1 New York Heart Association functional class was observed in 31% on placebo, and 43% and 64% on aficamten in Cohorts 1 and 2, respectively (nonsignificant). With aficamten, N-terminal pro–B-type natriuretic peptide was reduced. There were no treatment interruptions, and adverse events were similar between treatment arms. Clinical Implication and Meaning: Aficamten resulted in substantial reductions in the left ventricular outflow tract gradients with most patients experiencing improvement in biomarkers and symptoms. These results highlight the potential of sarcomere-targeted therapy for the treatment of oHCM. 5) Comparison of Antiplatelet Monotherapies after Percutaneous Coronary Intervention According to Clinical, Ischemic, and Bleeding Risks Yang S, Kang J, Park KW, Hur SH, Lee NH, Hwang D, et al. Comparison of antiplatelet monotherapies after percutaneous coronary intervention according to clinical, ischemic, and bleeding risks. J Am Coll Cardiol 2023;82:1565-78. New Question: The purpose of this study was to evaluate the benefits of clopidogrel across high-risk subgroups. Key Findings: Among 5403 patients, clopidogrel monotherapy showed a lower rate of the primary composite endpoint than aspirin monotherapy. The benefit of clopidogrel over aspirin was consistent regardless of Thrombolysis In Myocardial Infarction Risk Score for Secondary Prevention (TRS 2°P) and regardless of dual antiplatelet therapy (DAPT) score. The association was similar for the individual outcomes. Clinical Implication and Meaning: The beneficial effect of clopidogrel over aspirin monotherapy was consistent regardless of clinical risk or relative ischemic and bleeding risks compared with aspirin monotherapy. 6) Association of Coronary Artery Calcium Detected by Routine Ungated Computed Tomography Imaging with Cardiovascular Outcomes Peng AW, Dudum R, Jain SS, Maron DJ, Patel BN, Khandwala N, et al. Association of coronary artery calcium detected by routine ungated CT imaging with cardiovascular outcomes. J Am Coll Cardiol 2023;82:1192-202. New Question: The authors investigated whether incidental coronary artery calcium (CAC) quantified on routine nonelectrocardiography (ECG) -gated computed tomography scan (CT) using a deep-learning (DL) algorithm provided cardiovascular risk stratification beyond traditional risk prediction methods. Key Findings: Of 5678 adults without Atherosclerotic cardiovascular disease (ASCVD) (51% of women, 18% of Asian, and 13% of Hispanic/Latinx), 52% had DL-CAC >0. Those with DL-CAC ≥100 had an average 10-year ASCVD risk of 24%; yet, only 26% were on statins. After adjustment, patients with DL-CAC ≥100 had an increased risk of death, death/myocardial infarction (MI)/stroke, and death/MI/stroke/revascularization compared with DL-CAC = 0. 7) Postapproval Study of a Subcutaneous Implantable Cardioverter-defibrillator System Gold MR, El-Chami MF, Burke MC, Upadhyay GA, Niebauer MJ, Prutkin JM, et al. Postapproval study of a subcutaneous implantable cardioverter-defibrillator system. J Am Coll Cardiol 2023;82:383-97. New Question: The Subcutaneous Implantable Cardioverter-Defibrillator System Post Approval Study (S-ICD) is a real-world, multicenter, Registry of U.S. Centers that was designed to assess long-term S-ICD safety and efficacy in a diverse group of patients and implantation centers. Key Findings: A total of 1643 patients were prospectively enrolled, with a median follow-up of 4.2 years. All prespecified safety and efficacy endpoint goals were met. Shock efficacy rates for discrete episodes of ventricular tachycardia or ventricular fibrillation were 98.4%, and they did not differ significantly across follow-up years. S-ICD-related and electrode-related complication-free rates were 93.4% and 99.3%, respectively. Only 1.6% of patients had their devices replaced by a transvenous implantable cardioverter-defibrillator (TV-ICD) for a pacing need. The cumulative all-cause mortality was 21.7%. Clinical Implication and Meaning: In the largest prospective study of the S-ICD to date, all study endpoints were met, despite a cohort with more comorbidities than in most previous trials. Complication rates were low, and shock efficacy was high. These results demonstrate the 5-year S-ICD safety and efficacy for a large, diverse cohort of S-ICD recipients. 8) Regional Antibiotic Delivery for Implanted Cardiovascular Electronic Device Infections Topaz M, Chorin E, Schwartz AL, Hochstadt A, Shotan A, Ashkenazi I, et al. Regional antibiotic delivery for implanted cardiovascular electronic device infections. J Am Coll Cardiol 2023;81:119-33. New Question: The authors evaluated the efficacy of delivering continuous, in situ–targeted, ultrahigh concentration of antibiotics (CITA) into the infected subcutaneous device pocket, obviating the need for device/lead extraction. Key Findings: A total of 80 patients with pocket infections were treated with CITA during 2007–2021. CITA was curative in 85% of patients, who remained free of infection (median follow-up 3 years [interquartile range: 1.0–6.8 years]). In the case–control study of CITA versus device/lead extraction, cure rates were higher after device/lead extraction than after CITA. However, rates of serious complications were also higher after extraction. All-cause 1-month and 1-year mortality were similar for CITA and device/lead extraction. Extraction was avoided in 90.8% (n = 59 of 65) of extraction-eligible patients treated with CITA. Clinical Implication and Meaning: CITA is a safe and effective alternative for patients with pocket infections who are unsuitable or unwilling to undergo extraction. 9) Quantitative Coronary Angiography versus Intravascular Ultrasonography to Guide Drug-eluting Stent Implantation: A Randomized Clinical Trial Lee PH, Hong SJ, Kim HS, Yoon YW, Lee JY, Oh SJ, et al. Quantitative coronary angiography versus intravascular ultrasonography to guide drug-eluting stent implantation: A randomized clinical trial. JAMA Cardiol 2024;9:428-35. New Question: Could the systematic implementation of quantitative coronary angiography (QCA) to assist angiography-guided percutaneous coronary intervention (PCI) be an alternative to intravascular ultrasonography (IVUS)? Key Findings: The trial included 1528 patients who underwent PCI with QCA guidance (763; mean [standard deviation (SD)] age, 64.1 [9.9] years; 574 males [75.2%]) or IVUS guidance (765; mean [SD] age, 64.6 [9.5] years; 622 males [81.3%]). The post-PCI mean (SD) minimum lumen diameter was similar between the QCA- and IVUS-guided PCI groups (2.57 [0.55] vs. 2.60 [0.58] mm, P = 0 .26). Target lesion failure at 12 months occurred in 29 of 763 patients (3.81%) in the QCA-guided PCI group and 29 of 765 patients (3.80%) in the IVUS-guided PCI group. There was no difference in the rates of stent edge dissection, coronary perforation, or stent thrombosis between the QCA- and IVUS-guided PCI groups. The risk of the primary endpoint was consistent regardless of subgroup, with no significant interaction. Clinical Implication and Meaning: Findings of this randomized clinical trial indicate that QCA and IVUS guidance during PCI showed similar rates of target lesion failure at 12 months. However, due to the lower-than-expected rates of target lesion failure in this trial, the findings should be interpreted with caution. 10) Microplastics and Nanoplastics in Atheromas and Cardiovascular Events New Question: Microplastics and nanoplastics (MNPs) are emerging as a potential risk factor for cardiovascular disease in preclinical studies. Is there direct evidence that this risk extends to humans? Key Findings: A total of 304 patients were enrolled in the study, and 257 completed a mean (±standard deviation) follow-up of 33.7 ± 6.9 months. Polyethylene was detected in carotid artery plaque of 150 (58.4%) patients, with a mean level of 21.7 ± 24.5 μg/mg of plaque; 31 (12.1%) patients also had measurable amounts of polyvinyl chloride, with a mean level of 5.2 ± 2.4 μg/mg of plaque. Electron microscopy revealed visible, jagged-edged foreign particles among plaque macrophages and scattered in the external debris. Radiographic examination showed that some of these particles included chlorine. Patients in whom MNPs were detected within the atheroma were at higher risk for a primary endpoint event than those in whom these substances were not detected. Clinical Implication and Meaning: In this study, patients with carotid artery plaque in which MNPs were detected had a higher risk of a composite of myocardial infarction, stroke, or death from any cause at 34 months of follow-up than those in whom MNPs were not detected. 11) Transcatheter or Surgical Aortic Valve Implantation: Ten-year Outcomes of the Nordic Aortic Valve Intervention Trial Thyregod HG, Jørgensen TH, Ihlemann N, Steinbrüchel DA, Nissen H, Kjeldsen BJ, et al. Transcatheter or surgical aortic valve implantation: 10-year outcomes of the NOTION trial. Eur Heart J 2024;45:1116-24. New Question: Transcatheter aortic valve implantation (TAVI) has become a viable treatment option for patients with severe aortic valve stenosis across a broad range of surgical risks. The Nordic Aortic Valve Intervention trial was the first to randomize patients at lower surgical risk to TAVI or surgical aortic valve replacement (SAVR). The aim of the present study was to report clinical and bioprosthesis outcomes after 10 years. Key Findings: Baseline characteristics were similar between TAVI and SAVR: age 79.2 ± 4.9 years and 79.0 ± 4.7 years (P = 0.7), male 52.6% and 53.8% (P = 0.8), and Society of Thoracic Surgeons score
Zitieren
APA
Bhandari, S., Dey, N., Kumar, A., & Singh, S. (2024). Recent trials with a “high impact” on current daily practice a 360° journal search. Journal of Current Cardiology. https://doi.org/10.4103/jcc.jcc_17_24
Vancouver
Bhandari S, Dey N, Kumar A, Singh S. Recent trials with a “high impact” on current daily practice a 360° journal search. Journal of Current Cardiology. 2024. doi:10.4103/jcc.jcc_17_24
BibTeX
@article{Bhandari2024,
author = {Bhandari, Suman and Dey, Nilashish and Kumar, Akhilesh and Singh, Shailesh},
title = {Recent trials with a “high impact” on current daily practice a 360° journal search},
journal = {Journal of Current Cardiology},
year = {2024},
doi = {10.4103/jcc.jcc_17_24}
}
EUVIMED